Andrew K. Balo - Jun 3, 2021 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Officer
Signature
By: Jereme Sylvain For: Andrew K. Balo
Stock symbol
DXCM
Transactions as of
Jun 3, 2021
Transactions value $
-$896,625
Form type
4
Date filed
6/7/2021, 07:33 PM
Next filing
Jul 8, 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Other $0 -18.8K -53.17% $0.00 16.5K Jun 3, 2021 Direct F1, F2
transaction DXCM Common Stock Other $0 +18.8K $0.00 18.8K Jun 3, 2021 by Trust F1, F3
transaction DXCM Common Stock Sale -$897K -2.39K -12.74% $375.00 16.4K Jun 3, 2021 by Trust F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
F2 Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.
F3 Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
F4 On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Remarks:

*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development